Construction of a clickable probe-based protein chip platform for discovering covalent mIDH1 inhibitors from natural medicinal extracts

Abstract

The early discovery of covalent drugs is frequently inspired by, or derived from, natural sources, with such compounds often showing favorable safety profiles and a comparatively lower risk of clinical failure. However, a straightforward, high-throughput technique for screening covalent-binding molecules directly from complex medicinal plant extracts remains unavailable. In this study, we introduce an integrated strategy that combines protein microarrays with bioorthogonal click chemistry (Ccc-Chip). This platform includes a differential scanning fluorimetry (DSF)-based pre-screening step to enhance efficiency, with the Ccc-Chip serving as the core confirmation tool. It provides simple and intuitive readouts, enabling synchronous, high-throughput screening of covalent ligands targeting multiple proteins through detection of their competitive binding with cysteine-reactive probes. To validate the approach, we constructed a mutant isocitrate dehydrogenase 1 (mIDH1) protein microarray and used the integrated workflow to screen 110 medicinal plants. Our results led to the identification of flavokawain C (Flc), a covalent inhibitor of mIDH1, from Piper methysticum Forst. Subsequent in vivo experiments showed that Flc significantly reduced 2-hydroxyglutarate (2-HG) levels in an mIDH1-driven orthotopic tumor model and enhanced CD8⁺ T cell activity. Notably, when combined with a programmed cell death protein 1 (PD-1) blocking antibody, Flc synergistically augmented antitumor immunity, resulting in suppressed tumor growth. This work not only supports the high-throughput utility of the Ccc-Chip strategy but also provides a practical framework for combining bioorthogonal labeling with protein microarray technology, facilitating the discovery of bioactive covalent molecules from plant sources for challenging therapeutic targets.

Keywords

bioorthogonal click chemistry / covalent active molecules / flavokawain c / medicinal plants / mutant isocitrate dehydrogenase 1 inhibitor / natural product screening / protein microarray

References

[1] Singh, Juswinder. 2022. “The Ascension of Targeted Covalent Inhibitors.” Journal of Medicinal Chemistry 65: 5886–901. https://doi.org/10.1021/acs.jmedchem.1c02134

[2] Boike, Lydia, Nathaniel J. Henning, and Daniel K. Nomura. 2022. “Advances in Covalent Drug Discovery.” Nature Reviews Drug Discovery 21: 881–98. https://doi.org/10.1038/s41573-022-00542-z

[3] Kalgutkar, Amit S., Brenda C. Crews, Scott W. Rowlinson, Carlos Garner, Karen Seibert, and Lawrence J. Marnett. 1998. “Aspirin-Like Molecules That Covalently Inactivate Cyclooxygenase-2.” Science 280: 1268–70. https://doi.org/10.1126/science.280.5367.1268

[4] Godinez, William J., Helen Chan, Imtiaz Hossain, Cindy Li, Srijan Ranjitkar, Dita Rasper, Robert L. Simmons, Xian Zhang, and Brian Y. Feng. 2019. “Morphological Deconvolution of Beta-Lactam Polyspecificity in E. Coli.” ACS Chemical Biology 14: 1217–26. https://doi.org/10.1021/acschembio.9b00141

[5] Eisenreich, Wolfgang, Ernst Kupfer, Peter Stohler, Wolfgang Weber, and Adelbert Bacher. 2003. “Biosynthetic Origin of a Branched Chain Analogue of the Lipase Inhibitor, Lipstatin.” Journal of Medicinal Chemistry 46: 4209–12. https://doi.org/10.1021/jm030780x

[6] McNeely, Wendy, and Paul Benfield. 1998. “Orlistat.” Drugs 56: 241–9. discussion 250. https://doi.org/10.2165/00003495-199856020-00007

[7] Wen, Xiujuan, Chang Liu, Kiersten Tovar, Patrick Curran, Matthew Richards, Sony Agrawal, Richard Johnstone, et al. 2024. “High-Throughput Covalent Modifier Screening With Acoustic Ejection Mass Spectrometry.” Journal of the American Chemical Society 146: 19792–9. https://doi.org/10.1021/jacs.4c02377

[8] Johansson, Henrik, Yi-Chun Isabella Tsai, Ken Fantom, Chun-Wa Chung, Sandra Kümper, Luigi Martino, Daniel A. Thomas, et al. 2019. “Fragment-Based Covalent Ligand Screening Enables Rapid Discovery of Inhibitors for the RBR E3 Ubiquitin Ligase HOIP.” Journal of the American Chemical Society 141: 2703–12. https://doi.org/10.1021/jacs.8b13193

[9] Resnick, Efrat, Anthony Bradley, Jinrui Gan, Alice Douangamath, Tobias Krojer, Ritika Sethi, Paul P. Geurink, et al. 2019. “Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening.” Journal of the American Chemical Society 141: 8951–68. https://doi.org/10.1021/jacs.9b02822

[10] Siriwongsup, Surached, Anna M. Schmoker, Scott B. Ficarro, Jarrod A. Marto, and Justin Kim. 2024. “Bioorthogonally Activated Reactive Species for Target Identification.” Chem 10: 1306–15. https://doi.org/10.1016/j.chempr.2024.03.002

[11] Zhou, Ting-Ting, Yu Zheng, Man-Wen Zhang, Li-Hu Gong, Kai Guo, Xiao-Ping He, Yan-Chun Liu, et al. 2025. “Plant Defense-Directed Discovery of a Natural Anti-Psoriasis Agent Targeting GAPDH.” Science Advances 11: eadw2578. https://doi.org/10.1126/sciadv.adw2578

[12] Wang, Jigang, Chong-Jing Zhang, Wan Ni Chia, Cheryl C. Y. Loh, Zhengjun Li, Yew Mun Lee, Yingke He, et al. 2015. “Haem-Activated Promiscuous Targeting of Artemisinin in Plasmodium Falciparum.” Nature Communications 6: 10111. https://doi.org/10.1038/ncomms10111

[13] Ma, Teng, Xiao Tian, Baoding Zhang, Mengqi Li, Yu Wang, Chunyan Yang, Jianfeng Wu, et al. 2022. “Low-Dose Metformin Targets the Lysosomal AMPK Pathway Through PEN2.” Nature 603: 159–65. https://doi.org/10.1038/s41586-022-04431-8

[14] Meghani, Nilesh M., Hardik H. Amin, and Beom-Jin Lee. 2017. “Mechanistic Applications of Click Chemistry for Pharmaceutical Drug Discovery and Drug Delivery.” Drug Discovery Today 22: 1604–19. https://doi.org/10.1016/j.drudis.2017.07.007

[15] Lin, Chia-Chi, and Chien-Sheng Chen. 2025. “Bacterial Proteome Microarray Technology in Biomedical Research.” Trends in Biotechnology 43: 1317–27. https://doi.org/10.1016/j.tibtech.2024.12.001

[16] Cui, Zhao, Peng Chen, Caifeng Li, Shiwen Deng, and Hongjun Yang. 2022. “Chip-DSF: A Rapid Screening Strategy for Drug Protein Targets.” Pharmacological Research 182: 106346. https://doi.org/10.1016/j.phrs.2022.106346

[17] Han, Dong, Tingwen Zhou, Lifu Li, Yan Ma, Shiqi Chen, Chunguang Yang, Ning Ma, et al. 2024. “AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease.” Circulation 149: 1578–97. https://doi.org/10.1161/circulationaha.123.065213

[18] Dong, Renshun, Tianci Wang, Wei Dong, Haoquan Zhang, Yani Li, Ran Tao, Qiumeng Liu, et al. 2025. “TGM2-Mediated Histone Serotonylation Promotes HCC Progression via MYC Signalling Pathway.” Journal of Hepatology 83: 105–18. https://doi.org/10.1016/j.jhep.2024.12.038

[19] Cui, Zhao, Caifeng Li, Wei Liu, Mo Sun, Shiwen Deng, Junxian Cao, Hongjun Yang, and Peng Chen. 2024. “Scutellarin Activates IDH1 to Exert Antitumor Effects in Hepatocellular Carcinoma Progression.” Cell Death & Disease 15: 267. https://doi.org/10.1038/s41419-024-06625-6

[20] Cui, Zhao, Jiameng Li, Caifeng Li, Shiwen Deng, Wei Liu, Tong Lei, Junxian Cao, et al. 2025. “Identifying the Target, Mechanism, and Agonist of α-Ketoglutaric Acid in Delaying Mesenchymal Stem Cell Senescence.” Cell Reports 44: 115917. https://doi.org/10.1016/j.celrep.2025.115917

[21] Liang, Qianmao, Beilei Wang, Fengming Zou, Gongrui Guo, Wenliang Wang, Wei Wang, Qingwang Liu, et al. 2023. “Structure-Based Discovery of IHMT-IDH1-053 as a Potent Irreversible IDH1 Mutant Selective Inhibitor.” European Journal of Medicinal Chemistry 256: 115411. https://doi.org/10.1016/j.ejmech.2023.115411

[22] Wu, Meng-Ju, Hiroshi Kondo, Ashwin V. Kammula, Lei Shi, Yi Xiao, Sofiene Dhiab, Qin Xu, et al. 2024. “Mutant IDH1 Inhibition Induces dsDNA Sensing to Activate Tumor Immunity.” Science 385: eadl6173. https://doi.org/10.1126/science.adl6173

[23] Farshidfar, Farshad, Siyuan Zheng, Marie-Claude Gingras, Yulia Newton, Juliann Shih, A Gordon Robertson, Toshinori Hinoue, et al. 2017. “Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.” Cell Reports 18: 2780–94. https://doi.org/10.1016/j.celrep.2017.02.033

[24] Dong, Liangqing, Dayun Lu, Ran Chen, Youpei Lin, Hongwen Zhu, Zhou Zhang, Shangli Cai, et al. 2022. “Proteogenomic Characterization Identifies Clinically Relevant Subgroups of Intrahepatic Cholangiocarcinoma.” Cancer Cell 40: 70–87.e15. https://doi.org/10.1016/j.ccell.2021.12.006

[25] Nakamura, Hiromi, Yasuhito Arai, Yasushi Totoki, Tomoki Shirota, Asmaa Elzawahry, Mamoru Kato, Natsuko Hama, et al. 2015. “Genomic Spectra of Biliary Tract Cancer.” Nature Genetics 47: 1003–10. https://doi.org/10.1038/ng.3375

[26] Mackay, Alan, Anna Burford, Diana Carvalho, Elisa Izquierdo, Janat Fazal-Salom, Kathryn R. Taylor, Lynn Bjerke, et al. 2017. “Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.” Cancer Cell 32: 520–37.e5. https://doi.org/10.1016/j.ccell.2017.08.017

[27] Hacker, Stephan M., Keriann M. Backus, Michael R. Lazear, Stefano Forli, Bruno E. Correia, and Benjamin F. Cravatt. 2017. “Global Profiling of Lysine Reactivity and Ligandability in the Human Proteome.” Nature Chemistry 9: 1181–90. https://doi.org/10.1038/nchem.2826

[28] Hahm, Heung Sik, Emmanuel K. Toroitich, Adam L. Borne, Jeffrey W. Brulet, Adam H. Libby, Kun Yuan, Timothy B. Ware, et al. 2020. “Global Targeting of Functional Tyrosines Using Sulfur-Triazole Exchange Chemistry.” Nature Chemical Biology 16: 150–9. https://doi.org/10.1038/s41589-019-0404-5

[29] Ma, Nan, Jun Hu, Zhi-Min Zhang, Wenyan Liu, Minhao Huang, Youlong Fan, Xingfeng Yin, et al. 2020. “2H-azirine-Based Reagents for Chemoselective Bioconjugation at Carboxyl Residues Inside Live Cells.” Journal of the American Chemical Society 142: 6051–9. https://doi.org/10.1021/jacs.9b12116

[30] Jakob, Clarissa G., Anup K. Upadhyay, Pamela L. Donner, Emily Nicholl, Sadiya N. Addo, Wei Qiu, Christopher Ling, et al. 2018. “Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315.” Journal of Medicinal Chemistry 61: 6647–57. https://doi.org/10.1021/acs.jmedchem.8b00305

[31] Sun, Jianbo, Hui Zhong, Kun Wang, Na Li, Li Chen, and Li Chen. 2021. “Gains from No Real PAINS: Where ‘Fair Trial Strategy’ Stands in the Development of Multi-Target Ligands.” Acta Pharmaceutica Sinica B 11: 3417–32. https://doi.org/10.1016/j.apsb.2021.02.023

[32] Sharma, Padmanee, Bilal A. Siddiqui, Swetha Anandhan, Shalini S. Yadav, Sumit K. Subudhi, Jianjun Gao, Sangeeta Goswami, and James P. Allison. 2021. “The Next Decade of Immune Checkpoint Therapy.” Cancer Discovery 11: 838–57. https://doi.org/10.1158/2159-8290.Cd-20-1680

RIGHTS & PERMISSIONS

2026 The Author(s). iMeta published by John Wiley & Sons Australia, Ltd on behalf of iMeta Science.